Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Appoints Dr. Roy D. Baynes to Board
- Nurix Therapeutics price target raised to $17 from $16 at Morgan Stanley
- Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory Shift
- Nurix Therapeutics Reports Solid Progress and Strong Pipeline
- Nurix Therapeutics price target raised to $27 from $26 at RBC Capital